| Memantine Hydrochloride Extended-release and Donepezil Hydrochloride | Allergan | ||
| 10/14mg , 10/28 mg; Capsule, Extended Release |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
Less Than 5
|
||
| None | None | ||
| Used to treat moderate to severe dementia of the Alzheimer's Patients | |||
|
Yes
| |||
| Memantine Hydrochloride Extended-release and Donepezil Hydrochloride | Allergan | ||
| 10/21 mg; Capsule, Extended Release |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
| None | None | ||
|
Less Than 5
|
None | ||
| None | |||
|
No
| |||
| Namzaric | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ******** ****** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ******** ****** | *** \ ********* | *** **, **** | ********* | ******** | ** *** **, **** |
Download ParaIV Report